US FDA regulatory woes dull Lupin’s growth revival allure
Remediation is a long-drawn process; restricts manufacturing and drug-filing capabilities key to generic drug firms
R. Sree Ram email@example.com
MARK TO MARKET
Despite the latest US Food and Drug Administration’s (FDA’s) stricture on one of its plants, Lupin Ltd’s stock didn’t react negatively. The stock was up marginally at ₹764.20 on Thursday. The US drug regulator classified the inspection of the company’s...
Read latest mint ePaper online.